Abstract
In recent years, there has been an increased effort in the development of therapies which target an epigenetic mode of action. Among thes e efforts include progress in the development of inhibitors of EZH2 (Enhancer of Zeste Homolog 2), a key epigenetic target with strong disease implications to cancer. Over the last 3+ years, multiple reports describing small molecule inhibitors of EZH2 have been described, including those for chemical probes and drug candidates which have entered the clinic as first-in-class agents. Recent progress in this emerging area is presented in this review.
Keywords: Chromatin, epigenetics, histone methyltransferases, nucleosome, post-translational modification.
Current Topics in Medicinal Chemistry
Title:Inhibition of the Histone Lysine Methyltransferase EZH2 for the Treatment of Cancer
Volume: 15 Issue: 8
Author(s): Sharad K. Verma
Affiliation:
Keywords: Chromatin, epigenetics, histone methyltransferases, nucleosome, post-translational modification.
Abstract: In recent years, there has been an increased effort in the development of therapies which target an epigenetic mode of action. Among thes e efforts include progress in the development of inhibitors of EZH2 (Enhancer of Zeste Homolog 2), a key epigenetic target with strong disease implications to cancer. Over the last 3+ years, multiple reports describing small molecule inhibitors of EZH2 have been described, including those for chemical probes and drug candidates which have entered the clinic as first-in-class agents. Recent progress in this emerging area is presented in this review.
Export Options
About this article
Cite this article as:
Verma K. Sharad, Inhibition of the Histone Lysine Methyltransferase EZH2 for the Treatment of Cancer, Current Topics in Medicinal Chemistry 2015; 15 (8) . https://dx.doi.org/10.2174/1568026615666150302105207
DOI https://dx.doi.org/10.2174/1568026615666150302105207 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Th17 Cells in Airway Diseases
Current Molecular Medicine Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Administration of Drug and Nutritional Components in Nano-Engineered Form to Increase Delivery Ratio and Reduce Current Inefficient Practice
Recent Patents on Drug Delivery & Formulation Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nanoparticle-Based Combination Therapy for Cancer Treatment
Current Pharmaceutical Design Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry Designing Proteins That Work Using Recombinant Technologies
Current Pharmaceutical Biotechnology Stem Cell Transplantation for Chronic Myeloid Leukemia (CML): Current Indications and Perspectives
Current Cancer Drug Targets